Efficacy and Safety of Paclitaxel-Based PD-1/PD-L1 Immunotherapies for Triple-Negative Breast Cancer: A Systematic Review and Network Meta-Analysis

Efficacy and Safety of Paclitaxel-Based PD-1/PD-L1 Immunotherapies for Triple-Negative Breast Cancer: A Systematic Review and Network Meta-Analysis

Background: Triple negative breast cancer (TNBC) is a deadly subtype of breast cancer with limited treatment options. Currently, programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors have become the first choice for breast cancer immunotherapies. Despite paclitaxel being considered...

Full description

Saved in:
Bibliographic Details
Main Authors: Youran Dai, Tianyin Ruan, Wenhui Yang, Shan Liu, Jiahao Chen, Yingying Fang, Qiushuang Li
Format: Article
Language:English
Published: SAGE Publishing 2024-12-01
Series:Clinical Medicine Insights: Oncology
Online Access:https://doi.org/10.1177/11795549241308072
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items